top of page

Cytiva fuels biotech development in Australia and New Zealand

07/02/22 - VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines.

Part of Cytiva’s BioChallenge global series, the inaugural challenge for the Australia and New

Zealand region received 32 applications from various universities and companies.

Cytiva, a global life sciences leader, announces the winner of its first BioChallenge for the

Australia and New Zealand region (ANZ). The competition attracted 32 proposals from

academic institutions and start-up companies across the region’s biotechnology industry. They were evaluated by a panel of independent judges. VivaZome Therapeutics, an emerging exosome-derived therapies developer, was ultimately awarded the top prize valued at approximately AUD $200,000.

Since the global BioChallenge was launched in 2018, Cytiva has overseen more than 130

projects. The company has provided approximately four million USD of products and services to support research, bioprocessing development, and commercialization. In the first ANZ BioChallenge, the focus was on empowering biotech researchers and companies in three areas: cell engineering, process development and isolation as well as chromatography and filtration purification.

VivaZome's winning entry depicted the company’s efforts to develop a universal exosome

manufacturing process, with an aim is to produce off-the-shelf regenerative medicines without existing hurdles of delivering live cells to patients. Professor David Haylock, CEO of VivaZomeTherapeutics, says “Our team is working to be a global leader in providing novel, valuable and safe exosome-derived therapies for devastating and life-threatening diseases. To make ourvision real, we value the opportunity provided by BioChallenge to download industry experience and know-how from Cytiva.”

Read the full news article below -

Cytiva News - ANZ Biochallenge 2022
Download PDF • 58KB



bottom of page